Pfizer breast cancer drug hits midstage study goal

Published



Drugmaker Pfizer Inc. said Monday that a midstage study of its experimental drug for advanced breast cancer, palbociclib, met the main goal.

The world’s second-biggest drugmaker said the drug, combined with another medicine called letrozole, increased the time patients survived without tumors growing, compared with women just getting letrozole.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.